#### 1 **A Mul�-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse** 2 **Genome-Wide Associa�on Study and Popula�on-Specific Op�miza�on**

- 3
- *Johanna L. Smith, Ph.D.\*1 , Catherine Tcheandjieu, DVM, Ph.D.\*2,3,4,5, Ozan Dikilitas, M.D.1* 4 *, Kruthika Iyer,*
- *Ph.D.6 , Kazuo Miyazawa, M.D., Ph.D.7 , Austin Hilliard, Ph.D.4,6, Julie Lynch, Ph.D.8* 5 *, Jerome I. Rotter, M.D.,*
- *Ph.D.9 , Yii-Der Ida Chen, Ph.D.9 , Wayne Huey-Herng Sheu10,11,12, Kyong-Mi Chang, M.D.13* 6 *, Stavroula*
- *Kanoni, Ph.D.<sup>14</sup>, Phil Tsao, Ph.D. <sup>4,15</sup>, Kaoru Ito, M.D., Ph.D.<sup>7</sup>, Matthew Kosel, B.S.<sup>16</sup>, Shoa L. Clarke,*
- *Ph.D.4,15, Daniel J. Schaid, Ph.D.16, Themistocles L. Assimes, Ph.D.#15, Iftikhar J. Kullo, M.D. #1* 8
- 9
- 10 <sup>1</sup> Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
- 11 <sup>2</sup> Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, 12 USA.
- 13 <sup>3</sup> Gladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA.
- 
- <sup>4</sup> VA Palo Alto Health Care System, Palo Alto, CA, USA.<br>15 <sup>5</sup> Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine.
- 16 Stanford, CA, USA.
- 17 <sup>6</sup> Stanford University School of Medicine, Palo Alto, CA, USA.
- 18  $\frac{7}{18}$  Riken Ctr. for Integrative Medical Sciences, Yokohama City, Japan.
- 19 <sup>8</sup> Salt Lake City VA Met CTR., Salt Lake City, UT, USA.
- 20 <sup>9</sup> Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Lundquist
- 21 Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
- 22 <sup>10</sup> Institute of Molecular and Genomic Medicine, National Health Research Institutes, Taiwan.
- 23 <sup>11</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Veterans General
- 24 Hospital, Taipei, Taiwan.
- 25 <sup>12</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans
- 26 General Hospital, Taichung, Taiwan.
- 27 <sup>13</sup> Corporal Michael J Crescenz VA Medical Ctr. Philadelphia, PA, USA.
- 28 <sup>14</sup> Queen Mary University of London, Cambridge, UK.
- 29 <sup>15</sup> Stanford University, Stanford, CA, USA.
- 30 <sup>16</sup> Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
- 32 \* Co-first Authors
- 33 # Corresponding Authors
- 34

- 35 Iftikhar J. Kullo, 200 First St SW, Rochester MN, 55905, Kullo.Iftikhar@mayo.edu
- 36 Themistocles Assimes, Stanford University, Stanford, CA, USA.

#### 37 **Abstract (250 words)**

38 **Background:** Predictive performance of polygenic risk scores (PRS) varies across populations. To facilitate 39 equitable clinical use, we developed PRS for coronary heart disease (PRS $_{\text{CHD}}$ ) for 5 genetic ancestry 40 groups.

- 41 **Methods:** We derived ancestry-specific and multi-ancestry PRS<sub>CHD</sub> based on pruning and thresholding
- 42 (PRS<sub>P+T</sub>) and continuous shrinkage priors (PRS<sub>CSx</sub>) applied on summary statistics from the largest multi-
- 43 ancestry genome-wide meta-analysis for CHD to date, including 1.1 million par�cipants from 5
- 44 continental populations. Following training and optimization of PRS<sub>CHD</sub> in the Million Veteran Program,
- 45 we evaluated predictive performance of the best performing PRS<sub>CHD</sub> in 176,988 individuals across 9
- 46 cohorts of diverse genetic ancestry.
- 47 **Results:** Multi-ancestry PRS<sub>P+T</sub> outperformed ancestry specific PRS<sub>P+T</sub> across a range of tuning values. In
- 48 training stage, for all ancestry groups, PRS<sub>CSX</sub> performed better than PRS<sub>P+T</sub> and multi-ancestry PRS
- 49 outperformed ancestry-specific PRS. In independent validation cohorts, the selected multi-ancestry
- 50 PRS<sub>P+T</sub> demonstrated the strongest association with CHD in individuals of South Asian (SAS) and
- 51 European (EUR) ancestry (OR per 1SD[95% CI]; 2.75[2.41-3.14], 1.65[1.59-1.72]), followed by East Asian
- 52 (EAS) (1.56[1.50-1.61]), Hispanic/La�no (HIS) (1.38[1.24-1.54]), and weakest in African (AFR) ancestry
- 53  $(1.16[1.11-1.21])$ . The selected multi-ancestry PRS<sub>CSx</sub> showed stronger association with CHD in
- 54 comparison within each ancestry group where the association was strongest in SAS (2.67[2.38-3.00]) and
- 55 EUR (1.65[1.59-1.71]), progressively decreasing in EAS (1.59[1.54-1.64]), HIS (1.51[1.35-1.69]), and
- 56 lowest in AFR (1.20[1.15-1.26]).
- 57 **Conclusions:** Utilizing diverse summary statistics from a large multi-ancestry genome-wide meta-analysis
- 58 led to improved performance of PRS<sub>CHD</sub> in most ancestry groups compared to single-ancestry methods.
- 59 Improvement of predictive performance was limited, specifically in AFR and HIS, despite use of one of
- 60 the largest and most diverse set of training and validation cohorts to date. This highlights the need for
- 61 larger GWAS datasets of AFR and HIS individuals to enhance performance of PRS $_{CHD}$ .

## 62 **Introduction**

63 Coronary heart disease (CHD) is a leading cause of death in the United States (U.S.) and 64 worldwide <sup>1</sup>. CHD has an estimated heritability of 40-60% and the majority of the heritable risk is 65 attributable to a polygenic component, i.e., the aggregation of modest effects across many genetic 66 variants <sup>2</sup>. Polygenic risk scores (PRS) capture a proportion of that heritability and are typically 67 constructed by summing the products of the effect-size and the number of risk alleles at associated loci  $58$   $3,4$ . PRS for CHD have evolved over the last decade as progressively larger genome wide association 69 studies (GWAS) have been reported  $5-8$ . These PRS have been evaluated in several studies and are 70 associated with incident CHD independent of conventional risk factors such as hypertension, 71 hypercholesterolemia, diabetes, and smoking as well as family history of CHD  $8-10$ .

72 Most PRS for CHD have been developed, optimized, and validated in cohorts consisting largely of 73 individuals of European (EUR) ancestry (here and throughout the manuscript 'ancestry' refers to genetic 74 ancestry)  $11-14$ . Furthermore, the portability of these PRS to non-EUR groups is impacted by differences in 75 allele frequencies (AF), effect sizes, and linkage disequilibrium (LD) paterns across ancestry groups, 76 typically resulting in reduced predictive performance as studied populations diverge in these factors; an 77 observation most notable between EUR and African (AFR) ancestry populations  $6,11,15$ . We previously 78 observed significantly lower performance of several EUR-derived PRS for CHD in AFR ancestry individuals  $16,17$ . To prevent exacerbation of health disparities in the context of genomic medicine, there is a need to 80 improve performance of PRS for CHD for non-EUR populations.

81 In this study, we leveraged a large scale, ancestrally diverse genome-wide meta-analysis for CHD 82 to construct PRS for CHD optimized for EUR, AFR, Hispanic/Latino (HIS), East Asian (EAS), and South Asian 83 (SAS) ancestries. To this end, we utilized two PRS derivation methods, pruning and thresholding (P+T) 84 and the continuous shrinkage prior based PRS-CSx  $8,18$ . We assessed the performance of the multi-85 ancestry PRS in individuals with diverse ancestry belonging to 8 independent validation cohorts. Finally, a 86 PRS was selected for clinical implementation in the electronic Medical Records and Genomics (eMERGE) 87 network phase IV study in which PRS-informed risk profiles for several common conditions are being 88 returned to participants  $19$ .

89

### <sup>90</sup> **Methods**

#### 91 **GWAS Summary Sta�s�cs for PRS Development**

92 We developed PRS using both ancestry-specific and mul�-ancestry meta-analysis summary 93 statistics from a large-scale multi-ancestry GWAS for CHD including 1.1 million diverse participants with 94 243,392 CHD cases  $^{17}$ . This diverse meta-analysis included 17,202 AFR, 6,378 HIS, 29,319 EAS, and 95 190,776 EUR individuals with CHD belonging to four cohorts including the Million Veteran Program 96 (MVP), the UK Biobank (UKBB), CARDIoGRAMplusC4D Consor�um (2015 release), and Biobank Japan 97 (BBJ) (Figure 1)  $17,20-22$ .

98 We used two distinct methods to construct PRS, namely, pruning and thresholding (P+T) and the 99 continuous shrinkage prior based PRS-CSx  $8,18$ . Ancestry-specific PRS were defined from ancestry-specific

100 GWAS summary statistics (i.e., EUR specific summary statistics were used to develop a EUR specific PRS),

- 101 and multi-ancestry PRS were defined as PRS derived from multi-ancestry summary statistics. These PRS
- 102 were then trained and optimized in a separate set of individuals from the MVP and externally validated
- 103 in several diverse cohorts including the Atherosclerosis Risk in Communities (ARIC)  $^{23}$ , Multi-Ethnic Study
- 104 of Atherosclerosis (MESA)  $^{24}$ , Cardiovascular Health Study (CHS)  $^{25}$ , Women's Health Initiative (WHI)  $^{26}$ ,
- 105 eMERGE Phases I-III genotyped cohort  $^{27}$ , Biobank Japan (BBJ)  $^{28}$ , Osaka Acute Coronary Insufficiency
- 106 (OACIS) study <sup>29</sup>, the TAICHI Consortium <sup>30</sup>, and individuals of SAS ancestry from the UKBB <sup>31</sup> (Table S1;
- 107 Supplemental File 1).

#### 108 **Pruning and Thresholding (P+T)**

- 109 We derived two independent sets of PRS (ancestry-specific and multi-ancestry PRS) in two sequential
- 110 steps: First, we excluded from the base GWAS summary statistics, correlated single nucleotide variants
- 111 (SNVs) by LD pruning, applying 4 different  $R^2$  thresholding values (0.2, 0.5, 0.8, and 0.9) and 2 different
- 112 window distances (250kb and 500kb) within which these  $R^2$  were applied. LD pruning for ancestry-
- 113 specific PRS was performed based on reference panels comprised of 4,000 participants from each
- 114 respective ancestry (EUR, AFR, HIS, and ASN), selected among MVP participants included in the large-
- 115 scale GWAS for CHD. The LD pruning for the multi-ancestry PRS was performed on the full subset of
- 116 16,000 individuals from EUR, AFR, HIS, and ASN as the reference panel. This step generated 8 ancestry-
- 117 specific summary statistics and 8 multi-ancestry summary statistics for PRS development. Second, for
- 118 each newly generated summary statistic from step 1, we applied 16 different *p*-value thresholds (5×10<sup>-08</sup>,
- $119 \quad 1 \times 10^{-04}$ , 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1) (Figure S1; Supplemental
- 120 File 1). These led to 128 summary statistics within each ancestry, which were used to train the ancestry-
- 121 specific PRS. Similarly, we obtained 128 multi-ancestry-based summary statistics to train the multi-
- 122 ancestry PRS (PRS $_{P+T}$ ).

#### 123 **Con�nuous shrinkage (PRS-CSx)**

- 124 We applied a continuous shrinkage method, PRS-CSx (PRS<sub>CSx</sub>), on the effect sizes of a subset of 1.4 million
- 125 well curated HapMap SNVs on each ancestry-specific summary statistic. To identify the optimal shrinkage
- 126 parameter, we applied 4 different global shrinkage phi parameters (1,  $1e^{-0.2}$ ,  $1e^{-0.4}$ , and  $1e^{-0.6}$ ). LD
- 127 reference panels used were EUR, AFR, AMR and EAS from the 1000 Genomes project. The multi-ancestry
- 128 PRS were constructed from the meta-analysis of ancestry-specific summary statistics obtained after
- 129 applying the global shrinkage phi. For each ancestry, 4 ancestry-specific newly derived summary statistics
- 130 were obtained to train ancestry-specific PRS and 4 newly derived multi-ancestry summary statistics were 131 obtained for train the multi-ancestry PRS (Figure S2; Supplemental File 1). A total of 12 ancestry-specific
- 132 PRS (one for each global shrinkage parameter value used for each ancestry group and 4 multi-ancestry
- 133 PRS) were chosen for further development (Figure S3; Supplemental File 1).

#### 134 **PRS Training**

- 135 Following the construction of the ancestry-specific and multi-ancestry  $PRS_{P+T}$  and  $PRS_{CSX}$  across a range of
- 136 training specifications, we proceeded to assess their performance in an independent set of prevalent
- 137 cases and controls from the MVP (Figure 1B, PRS Training) using multivariable logistic regression with
- 138 adjustment for age at CHD event for cases and age at the last visit in the electronic health record (EHR)
- 139 for controls, year of birth, sex, and the first 5 principal components (PCs). We compared parameter

- 140 training on the multi-ancestry reference panel set versus population-specific reference panel. Ancestry-
- 141 specific PRS were evaluated in the corresponding ancestry, whereas the mul�-ancestry PRS were
- 142 evaluated in each ancestry. PRS with the highest observed odds ratio (OR) for CHD per 1 standard
- 143 deviation (SD) increase were deemed to have the optimal training parameter values across ancestry
- 144 populations and subsequently advanced for validation.

#### 145 **PRS Valida�on in the Million Veteran Program and Addi�onal External Cohorts**

- 146 Ancestry-specific and multi-ancestry PRS<sub>P+T</sub> and PRS<sub>CSx</sub> trained for each genetic ancestry group were
- 147 validated in an independent cohort from the MVP and several additional diverse cohorts (Figure 1C,
- 148 Diverse Cohorts for PRS Validation). The MVP validation cohort was restricted to incident cases of CHD
- 149 occurring after enrollment, and random controls, in a ratio of 1:10 (Figure 1C) as previously described
- 150 <sup>17</sup>. Four prospective cohorts, namely ARIC, MESA, CHS, WHI, a subset of the UKBB comprised of
- 151 individuals of SAS ancestry, and addi�onally eMERGE Phases I-III, contributed CHD incident cases and
- 152 controls of EUR, AFR, HIS, and SAS ancestry for PRS validation. Validation for EAS ancestry included
- 153 individuals from multiple case-control studies, namely Han Chinese participants from Taiwan as a part of
- 154 the TAICHI consor�um, as well as Japanese par�cipants from the BBJ and OACIS studies who were not
- 155 part of the multi-ancestry discovery GWAS  $30$ .

156 Within MVP, we used diagnosis and procedure codes to iden�fy individuals with any clinical 157 manifestation of CHD as previously described (Supplemental File 1)  $^{17}$ . This definition included both 158 'hard' (e.g., myocardial infarc�on, revasculariza�on) and 'so�' outcomes (e.g., angina, non-invasive study 159 positive for ischemia). In the 4 external validation NHLBI cohorts and the eMERGE cohort, cases were 160 restricted to myocardial infarction and revascularization. Prevalent cases were defined as all other cases 161 meeting diagnosis/procedure code criteria at the time of enrollment. Additional study details are

162 included in Supplemental File 1.

163 We calculated OR per 1-SD increase in PRS using multivariable logistic regression across all 164 validation cohorts. The dbGaP, eMERGE, and UKBB cohorts were adjusted for genetic ancestry using a 165 continuous correction further defined in the Supplemental File 1 (Figure S4). The two EAS case-control 166 studies were meta-analyzed using a fixed effect inverse-variance weighted model  $32$ . For all external 167 validation cohorts, we additionally estimated OR for CHD for participants in the top 5% of PRS 168 distribution compared to the rest, as well as area under the curve (AUC) discrimination statistic. 169 Calibration was also assessed using the calibration function in the rms package in R to assess portability 170 to cohorts that were not available for meta-analysis (i.e., the non-EAS cohorts) (Figure S5, Supplemental 171 File 2)  $33,34$ .

### <sup>172</sup> **Results**

#### 173 **PRS Training**

#### 174 **Pruning and Thresholding (P+T)**

175 Performance of the ancestry-specific and multi-ancestry  $PRS_{P+T}$  in each population is shown in Figure 2.

176 The multi-ancestry PRS<sub>P+T</sub> systematically outperformed ancestry-specific PRS<sub>P+T</sub> with noticeably higher OR

177 per SD except for the HIS ancestry group where the performance was similar (Figure 2, Supplemental

178 Figure S2). The multi-ancestry PRS<sub>P+T</sub>, performed best in HIS population, followed by the ASN population

- 179 (1.78 and 1.73 OR per SD, respectively) (Supplemental File 2). Prediction performance of the PRS<sub>P+T</sub> for
- 180 each ancestry was optimal at different p-value thresholds (Figure 2, Supplemental Figure S2). The multi-
- 181 ancestry PRS<sub>P+T</sub> performed best at  $R^2 \le 0.8$  with LD blocks of 250 kb, *p*-value threshold of 0.01 for AFR,
- 182 0.03 for EUR, and 0.30 for HIS. However, the differences between these PRS and the PRS optimized at
- 183  $R^2 \leq 0.8$  and a *p*-value = 0.01 were marginal, and the multi-ancestry PRS with a *p*-value threshold of
- 184 0.01 was chosen for validation in additional external cohorts.

#### 185 **Con�nuous shrinkage (PRS-CSx)**

- 186 The performances of the 12 ancestry-specific PRS<sub>CSx</sub> and 3 multi-ancestry PRS<sub>CSx</sub> built using EUR, AFR,
- 187 HIS, and EAS summary statistics at various global shrinkage phi values for tuning (1 $e^{-0.2}$ , 1 $e^{-0.4}$ , and
- 188  $1e^{-06}$ ) are shown in Figure 2. For all ancestry groups,  $phi = 1e^{-02}$  resulted in the best predictive
- 189 performance for PRS<sub>CSx</sub> and the multi-ancestry PRS outperformed ancestry-specific PRS at this phi value.
- 190 For the EUR population, both the EUR-derived PRS and the multi-ancestry PRS performed similarly, but
- 191 ASN and HIS populations performed best with the EUR-derived PRS, while the AFR population performed
- 192 best with the multi-ancestry PRS (Figure 2, Supplemental File 2). Overall, the multi-ancestry PRS<sub>CSx</sub> for the
- 193 ASN population resulted in the highest OR per/SD increase followed by EUR and HIS populations where
- 194 the strength of association was similar, and lowest in the AFR ancestry.
- 195

#### 196 **PRS Validation**

#### 197 **Million Veteran Program**

- 198 Ancestry specific PRS<sub>P+T</sub> predictive performance (OR per 1 -SD increase) for EUR (1.52), AFR (1.19), and
- 199 HIS (1.81) was compared to the ancestry-specific PRS<sub>CSx</sub> performance for EUR (1.66), AFR (1.15), HIS
- 200 (1.42), and ASN (1.32) (Figure 2; Supplemental File 2). This was also compared to the mul�-ancestry-
- 201 based methods using the same PRS training, i.e., the multi-ancestry PRS<sub>P+T</sub> for EUR (1.57), AFR (1.22), HIS
- 202 (1.78), and ASN (1.73), as well as PRS<sub>CSx</sub> for EUR (1.98), AFR (1.23), HIS (1.94), and ASN (2.06) (Figure 2;
- 203 Supplemental File 2). Of all the methods assessed at this step, the best performing methods tended to
- 204 be the multi-ancestry PRS<sub>CSx</sub> and multi-ancestry PRS<sub>P+T</sub>. However, there were overlapping confidence
- 205 intervals (CIs) with some single ancestry methods and the single-ancestry  $PRS_{CS}$  for EUR performed well 206 in other ancestries, so we decided to further assess the three methods (Figure 2).
- 207 We advanced the ancestry optimized PRS $_{P+T}$  and PRS<sub>CSx</sub>, for validation in an independent set of
- 208 incident cases and matching controls in ancestry groups of EUR, AFR, HIS, EAS, and SAS individuals.
- 209 Predictive performances of the multi-ancestry PRS were assessed within each ancestry group in
- 210 reference to a previously reported genome-wide PRS (i.e., PRS $_{\text{metaGRS}}$  <sup>10</sup>) constructed using a cohort of
- 211 predominantly of EUR ancestry (Figure 3)<sup>17</sup>. In this independent validation cohort, the multi-ancestry 212 PRS<sub>P+T</sub> and PRS<sub>CSx</sub> had a higher predictive performance compared to metaGRS (Figure 3). The multi-
- 213 ancestry PRS<sub>CSx</sub> had a relative increase in the estimated OR per 1-SD of 12% and 23% in reference to
- 214 PRS<sub>P+T</sub> and PRS<sub>metaGRS</sub>, respectively, averaged across all three genetic ancestries.
- 215

#### 216 **Additional External Validation Cohorts**

217 The best performing PRS<sub>P+T</sub> were further validated in several additional cohort and case-control studies

- 218 of CHD including EUR, AFR, HIS, EAS, and SAS participants (Table 1). ORs for ancestry-specific and multi-
- 219 ancestry PRS<sub>P+T</sub> ranged from 1.16 in AFR to 2.75 in SAS and were comparable to published reports,
- 220 despite inclusion of the diverse meta-analysis of GWAS (Supplemental File 2)<sup>6,17,35,36</sup>. All populations had
- 221 OR estimates for the top 5% vs the rest of the population  $\geq 2.16$  for PRS<sub>P+T</sub> except for AFR (1.68).

222 The two best performing PRS $_{\text{c}xx}$  in the training dataset, a EUR-tuned PRS and a multi-ancestry 223 PRS, both with a tuning global phi value of  $1e^{-0.2}$ , demonstrated similar performances in our validation

- 224 cohorts (Table 1, Table S2; Supplemental File 1) as the multi-ancestry PRS marginally outperformed the
- EUR-tuned PRS in all but the AFR and HIS cohorts. Point estimates of the OR for subjects in the top 5<sup>th</sup>
- 226 percentile of scores compared to the remaining participants shifted trend compared to those observed
- 227 for the ORs per 1-SD for AFR, HIS, and SAS populations, but these differences were in the context of
- 228 mostly overlapping 95% confidence intervals. When comparing the multi-ancestry PRS<sub>P+T</sub> to PRS<sub>CSx</sub>, the
- 229 point estimates of ORs were similar but higher for the multi-ancestry  $PRS_{CSX}$  for EUR, AFR, HIS, and EAS
- 230 populations. The OR per 1-SD was lower for the multi-ancestry PRS<sub>CSx</sub> for the SAS population (Table 1).
- 231

## <sup>232</sup> **Discussion**

233 Using summary statistics from the largest multi-ancestry GWAS meta-analysis for CHD to date and 9

234 independent validations cohorts, cumulatively comprised of 1.1 million diverse participants including

- 235 nearly a quarter of a million CHD cases of EUR, AFR, HIS, EAS, and SAS descent <sup>17</sup>, we developed, trained,
- 236 and validated multi-ancestry and ancestry-specific PRS models to address the gap in predictive

237 performance that currently exists between EUR and non-EUR ancestries.

238 We observed that the use of summary statistics from a multi-ancestry GWAS meta-analysis, in 239 comparison to the use of ancestry-specific summary statistics, improved PRS performance in majority of 240 the ancestry groups. PRS that leveraged shared information between ancestries to estimate SNV weights 241 (i.e., PRS<sub>CSx</sub>) modestly outperformed the P+T method (i.e., PRS<sub>P+T</sub>). Based on the multi-ancestry informed 242 PRS<sub>CSx</sub>, individuals in the high-genetic risk group (i.e., top 5% of the PRS distribution) compared to the 243 remaining participants in the respective ancestry group (EUR, AFR, HIS, EAS, and SAS), had 2.5-fold, 1.7-244 fold, 2.5-fold, 2.3-fold, and 5-fold increased risk of CHD, respectively. These results collectively highlight 245 complementary effects of integrating summary statistics from multiple ancestries and the use of PRS 246 derivation methods that leverage shared information and LD diversity between ancestry groups to 247 improve polygenic risk prediction for CHD.

248 Although remarkable progress has been achieved to date in both genomic discovery and 249 polygenic risk prediction among EUR cohorts  $5,7-10,37-39$ , similar progress has not occurred among non-EUR 250 populations due to their underrepresentation in genomic studies  $11-14$ . In recent years, the number of 251 large-scale multi-ancestry GWAS and polygenic risk prediction studies have increased with the 252 establishment of ancestrally diverse biobanks and collaborations efforts <sup>17,18,30,40-43</sup>. Several multi-253 ancestry genomic studies, including for glycemic, hematologic and lipid traits as well as disease 254 phenotypes such as type 2 diabetes and CHD, have increased the number of discovered loci, and 255 improved fine-mapping and cross-population polygenic risk prediction with inclusion of non-EUR

256 participants  $17,40-42,44$ . Our findings are consistent with these results in that integration of summary 257 statistics from several distinct ancestry groups improved predictive performance of PRS for all ancestries, 258 including EUR descent. One possible explanation for these observations is identification of potential 259 causal variants that are more likely to be shared between ancestries but are obscured by population-260 specific LD patterns <sup>14,45</sup>. Another likely contributing factor to improved PRS performance is reduced 261 noise in SNV effect size estimates resulting from both weighted average of population-level estimates 262 and increased total sample size  $46,47$ .

263 Despite the use of the largest ancestrally diverse cohort available to date, the improvement in 264 the predictive performance of PRS<sub>CHD</sub> was limited in individuals of AFR ancestry compared to other 265 ancestry groups. Prior reports investigating portability of PRS between populations noted that prediction 266 performance across a range of traits and phenotypes  $6,11,15,16,48,49$  decayed with increasing genetic 267 distance between study cohorts. Among the continental ancestry groups included in this study, AFR is 268 the most genetically distant population from EUR and hence the modest increase in prediction 269 performance with a multi-ancestry PRS<sub>CHD</sub> compared to the ancestry-specific counterpart. A recent 270 report showed similar heritability for CHD in the major continental ancestry groups but absence of two 271 common haplotypes at the 9p21 locus in AFR individuals, which corresponds to the largest effect locus in 272 EUR ancestry individuals <sup>17</sup>. These findings suggest potentially a larger role of ancestry-specific causal 273 variants in individuals of African origin with regards to heritability for CHD.

274 Although the strength of association of PRS with CHD varied between ancestry groups, it is 275 important to consider epidemiological differences in CHD risk across these populations. In clinical 276 practice, primary prevention guidelines for CHD use absolute risk estimates for clinical decision making, 277 such as 10-year or lifetime risk of a CHD event <sup>50</sup>. Individuals are typically classified into different risk 278 groups (e.g., low, borderline, intermediate, high risk) with a correlating intensity of pursued preventive 279 measures. In the United States, African American and South Asian populations have substantially higher 280 atherosclerotic cardiovascular disease (ASCVD) related mortality rates compared to non-Hispanic whites 281  $^{1,51}$ . Therefore, in a future risk model for ASCVD similar to the pooled cohort equation  $^{52}$ , incorporation of 282 a PRS for CHD with a narrower risk gradient in African Americans, compared to a much wider gradient in 283 non-Hispanic whites, could have more impact on re-classification into a higher risk group as we have 284 previously shown  $6$ .

285 Implementation of PRS in the clinical setting has begun for CHD, including at Mayo Clinic, where 286 a PRS for CHD is available in the clinical setting, based on the results of the MIGENES clinical trial  $^{53}$ . The 287 eMERGE Network, in its phase IV study is returning risk assessments to participants for 11 common 288 conditions, including CHD <sup>19</sup>. The multi-ancestry PRS<sub>P+T</sub> for CHD validated in this study <sup>19</sup> will be returned 289 to eMERGE participants. One of the major challenges in the clinical use of PRS include variable 290 performance between genetic ancestry populations  $11,15$ . Developing robust PRS for diverse ancestry 291 groups is crucial to avoid worsening existing health disparities  $11$  and a National Institute of Health (NIH) 292 funded initiative is addressing this as a priority  $54$ . The active recruitment and inclusion of diverse 293 participants and continued development of novel PRS methods that target improvement of cross-294 population prediction using a variety of approaches (e.g., incorporation of local ancestry  $^{55}$ , weighting by 295 trans-ancestry genetic correlation  $56$ , and informing by fine-mapping and functional annotation  $57,58$ ) will

296 be necessary for equitable implementation of PRS. Consequently, we anticipate that PRS for CHD will 297 continue to evolve and improve over time.

298

#### **299** Study Limitations

300 Despite the large and diverse composition of our study, the external validation for the SAS ancestry was 301 limited to a single cohort with a modest number of cases, reducing the precision of the associated risk 302 estimates. We were not able to include smoking status or family history in the models as the data was 303 not available for all cohorts, and this may have affected the strength of the association of PRS with CHD 304 in our analyses.

305

## <sup>306</sup> **Conclusions**

307 We demonstrated that incorporation of summary statistics from diverse genetic ancestry groups, as

308 opposed to individual ancestry groups alone, and leveraging shared information between these

309 populations, led to improved performance of PRS<sub>CHD</sub> in majority of the ancestry groups. Despite

310 utilization of one of the largest and most ancestrally diverse set of training and validation cohorts to

311 date, the gain in predictive performance for AFR was limited. Ongoing work is needed to narrow the

312 persistent performance gap for AFR ancestry individuals. Increasing AFR representation at each stage of

313 PRS development is necessary to lessen performance dispari�es, and such efforts should be a priority for

314 the community of genomics researchers.

315

# <sup>316</sup> **Acknowledgements**

317 We acknowledge the investigators and participants of the electronic Medical Records and Genomics

318 (eMERGE) Network. Infrastructure for the CHARGE Consortium is supported in part by the National

319 Heart, Lung, and Blood Ins�tute (NHLBI) grant R01HL105756. This work was also supported in part by

320 the National Institutes of Health, National Heart, Lung, Long and Blood Institute (NHLBI) contract

321 1R01HL151855, R01HL146860, and the National Institute of Diabetes and Digestive and Kidney Diseases

322 contract UM1DK078616.

323

# <sup>324</sup> **Sources of Funding**

325 This work was supported by grants from the Polygenic Risk Methods in Diverse Populations (PRIMED)

326 Consortium through the National Human Genome Research Institute (NHGRI): grant U01 HG11710, the

327 electronic Medical Records and Genomics (eMERGE) Network funded by the NHGRI: grant U01

328 HG06379, a National Heart, Lung, and Blood: grant K24 HL137010, the Clinical Genome Resource

329 (ClinGEN) funded by the NHGRI: grant HG09650, and R35 GM140487.

## **Disclosures**

- **Conflict of Interest.** The authors declare that they have no conflict of interest.
- **Human and Animal Rights and Informed Consent.** This article used data from previously published
- human studies.

### **References**

- 1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, 337 Boehme AK, Buxton AE, et al. Heart Disease and Stroke Statistics—2023 Update: A Report From
- the American Heart Associa�on. *Circulation*. 2023;147. doi: 10.1161/cir.0000000000001123
- 2. Kullo IJ, Ding K. Mechanisms of Disease: the gene�c basis of coronary heart disease. *Nature*
- *Clinical Practice Cardiovascular Medicine*. 2007;4:558-569. doi: 10.1038/ncpcardio0982 341 3. Euesden J, Lewis CM, O'Reilly PF. PRSice: Polygenic Risk Score software. *Bioinformatics*.
- 2015;31:1466-1468. doi: htps://doi.org/10.1093/bioinforma�cs/btu848
- 343 4. Kullo IJ, Lewis CM, Inouye M, Martin AR, Ripatti S, Chatterjee N. Polygenic scores in biomedical research. *Nature Reviews Genetics*. 2022. doi: 10.1038/s41576-022-00470-z
- 345 5. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic Risk Prediction and a 2-Stage Risk Screening Strategy for Coronary Heart Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2013;33:2261-2266. doi: 10.1161/atvbaha.112.301120
- 6. Dikilitas O, Schaid DJ, Tcheandjieu C, Clarke SL, Assimes TL, Kullo IJ. Use of Polygenic Risk Scores 349 for Coronary Heart Disease in Ancestrally Diverse Populations. *Current Cardiology Reports.* 2022;24:1169-1177. doi: 10.1007/s11886-022-01734-0
- 7. O'Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA, O'Donnell CJ, Willer CJ, Natarajan P. Polygenic Risk Scores for Cardiovascular Disease: A Scien�fic Statement 353 From the American Heart Association. *Circulation*. 2022;146. doi: 10.1161/cir.0000000000001077
- 8. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, et al. Genome-wide polygenic scores for common diseases iden�fy individuals with 357 risk equivalent to monogenic mutations. *Nature Genetics*. 2018;50:1219-1224. doi: 10.1038/s41588-018-0183-z
- 359 9. Rapatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, et al. A mul�locus gene�c risk score for coronary heart disease: case-control and prospec�ve cohort analyses. *The Lancet*. 2010;376:1393-1400.
- 362 10. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, Lai FY, Kaptoge S, 363 Brozynska M, Wang T, et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implica�ons for Primary Preven�on. *J American Coll Cardiol*. 2018;72:1883-1893.
- 365 11. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health dispari�es. *Nature Genetics*. 2019;51:584-591. doi: 10.1038/s41588-019-0379-x
- 12. Manolio TA. Using the Data We Have: Improving Diversity in Genomic Research. *The American Journal of Human Genetics*. 2019;105:233-236. doi: 10.1016/j.ajhg.2019.07.008
- 370 13. Clarke SL, Assimes TL, Tcheandjieu C. The Propagation of Racial Disparities in Cardiovascular Genomics Research. *Circulation: Genomic and Precision Medicine*. 2021;14. doi: 10.1161/circgen.121.003178
- 14. Gurdasani D, Barroso I, Zeggini E, Sandhu MS. Genomics of disease risk in globally diverse popula�ons. *Nature Reviews Genetics*. 2019;20:520-535. doi: 10.1038/s41576-019-0144-0
- 375 15. Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, Daly MJ, Bustamante CD, 376 Kenny EE. Human Demographic History Impacts Genetic Risk Prediction across Diverse Popula�ons. *The American Journal of Human Genetics*. 2017;100:635-649. doi:
- 10.1016/j.ajhg.2017.03.004

 16. Dikilitas O, Schaid DJ, Kosel ML, Carroll RJ, Chute CG, Denny JC, Fedotov A, Feng Q, Hakonarson 380 H, Jarvik GP, et al. Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in Three Major Racial and Ethnic Groups. *The American Journal of Human Genetics*. 2020;106:707-716. doi: 10.1016/j.ajhg.2020.04.002

- 17. Tcheandjieu C, Zhu X, Hilliard AT, Clarke SL, Napolioni V, Ma S, Lee KM, Fang H, Chen F, Lu Y, et al. 384 Large-scale genome-wide association study of coronary artery disease in genetically diverse popula�ons. *Nature Medicine*. 2022;28:1679-1692. doi: 10.1038/s41591-022-01891-3
- 18. Ge T, Irvin MR, Patki A, Srinivasasainagendra V, Lin Y-F, Tiwari HK, Armstrong ND, Benoit B, Chen 387 C-Y, Choi KW, et al. Development and validation of a trans-ancestry polygenic risk score for type 2 388 diabetes in diverse populations. *Genome Medicine*. 2022;14. doi: 10.1186/s13073-022-01074-2
- 19. Linder J, Allworth A, Bland ST, Caraballo PJ, Chisholm R, Clayton EW, Crosslin D, Dikilitas O, 390 DiVietro A, Esplin ED, et al. Returning integrated genomic risk and clinical recommendations: the eMERGE study. *Genetics in Medicine*. 2023. doi: htps://doi.org/10.1016/j.gim.2023.100006 392 20. Van Der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides an Expanded View on
- the Gene�c Architecture of Coronary Artery Disease. *Circulation Research*. 2018;122:433-443. doi: 10.1161/circresaha.117.312086
- 21. Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low 396 S-K, Okada Y, et al. Large-scale genome-wide association study in a Japanese population iden�fies novel suscep�bility loci across different diseases. *Nature Genetics*. 2020;52:669-679. doi: 10.1038/s41588-020-0640-3
- 22. Nikpay M, Goel A, Won H-H, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, 400 Hopewell JC, et al. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nature Genetics*. 2015;47:1121-1130. doi: 10.1038/ng.3396
- 402 23. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objec�ves. *American Journal of Epidemiology*. 1989;129:687-702.
- 24. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, R. JD, Kronmal 405 R, Liu K, et al. Multi-Ethnic Study of Atherosclerosis: Objectives and Design. *American Journal of Epidemiology*. 2002;156:871-881. doi: htps://doi.org/10.1093/aje/kwf113
- 25. (CHS) M�CHSRG, Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, 408 Manolio TA, Mittelmark MB, et al. The cardiovascular health study: Design and rationale. Annals *of Epidemiology*. 1991;1:263-276. doi: htps://doi.org/10.1016/1047-2797(91)90005-W
- 410 26. Group TWsHIS. Design of the Women's Health Initiative Clinical Trial and Observational Study. *Controlled Clinical Trials*. 1998;19:61-109. doi: htps://doi.org/10.1016/S0197-2456(97)00078-0
- 27. Stanaway IB, Hall TO, Rosenthal EA, Palmer M, Naranbhai V, Knevel R, Namjou-Kahles B, Carroll RJ, Kiryluk K, Gordon AS, et al. The eMERGE genotype set of 83,717 subjects imputed to ~40 million variants genome wide and associa�on with the herpes zoster medical record phenotype. *Genetic Epidemiology*. 2019;43:63-81. doi: 10.1002/gepi.22167
- 28. Nagai A, Hirata M, Kamatani Y, Muto K, Matsuda K, Kiyohara Y, Ninomiya T, Tamakoshi A, Yamagata Z, Mushiroda T, et al. Overview of the Biobank Japan Project: Study design and profile. *Journal of Epidemiology*. 2017;27:S2-S8. doi: 10.1016/j.je.2016.12.005
- 29. Kurotobi T, Sato H, Kinjo K, Nakatani D, Mizuno H, Shimizu M, Imai K, Hori M, Group O. Reduced 420 Collateral Circulation to the Infarct-Related Artery in Elderly Patients with Acute Myocardial Infarc�on. *J American Coll Cardiol*. 2004;44:28-34. doi: doi:10.1016/j.jacc.2003.11.066
- 30. Assimes TL, Lee IT, Juang J-M, Guo X, Wang T-D, Kim ET, Lee W-J, Absher D, Chiu Y-F, Hsu C-C, et 423 al. Genetics of Coronary Artery Disease in Taiwan: A Cardiometabochip Study by the Taichi Consor�um. *PLOS ONE*. 2016;11:e0138014. doi: 10.1371/journal.pone.0138014

 31. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliot P, Green J, Landray M, et al. UK Biobank: An Open Access Resource for Iden�fying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Medicine*. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779 429 32. Evangelou E, Ioannidis JPA. Meta-analysis methods for genome-wide association studies and beyond. *Nature Reviews Genetics*. 2013;14:379-389. doi: 10.1038/nrg3472 33. Harrell Jr. FE. rms: Regression Modeling Strategies. R package version 6.3-0. 2022. 432 34. Van Calster B, McLernon DJ, Van Smeden M, Wynants L, Steyerberg EW. Calibration: the Achilles heel of predic�ve analy�cs. *BMC Medicine*. 2019;17. doi: 10.1186/s12916-019-1466-7 35. Mars N, Kerminen S, Feng Y-CA, Kanai M, Lall K, Thomas LF, Skogholt AH, dellaBriota Parolo P, Project TBJ, FinnGen, et al. Genome-wide risk predic�on of common diseases across ancestries in one million people. *Cell Genomics*. 2022;2. 36. Wang M, Menon R, MSanghamitra M, Patel AP, Chaffin M, Tanneeru D, Deshmukh M, Mathew 438 C, Apte S, Devanboo CS, et al. Validation of a Genome-Wide Polygenic Score for Coronary Artery Disease in South Asians. *Journal of the American College of Cardiology*. 2020;76:703-714. doi: htps://doi.org/10.1016/j.jacc.2020.06.024 37. Tada H, Melander O, Louie JZ, Catanese JJ, Rowland CM, Devlin JJ, Kathiresan S, Shiffman D. Risk predic�on by gene�c risk scores for coronary heart disease is independent of self-reported family history. *European Heart Journal*. 2016;37:561-567. doi: 10.1093/eurheartj/ehv462 444 38. Ding K, Bailey KR, Kullo IJ. Genotype-informed estimation of risk of coronary heart disease based on genome-wide associa�on data linked to the electronic medical record. *BMC Cardiovascular Disorders*. 2011;11:66. doi: 10.1186/1471-2261-11-66 39. Abraham G, Havulinna AS, Bhalala OG, Byars SG, De Livera AM, Yetukuri L, Tikkanen E, Perola M, Schunkert H, Sijbrands EJ, et al. Genomic predic�on of coronary heart disease. *European Heart Journal*. 2016;37:3267-3278. doi: 10.1093/eurheartj/ehw450 40. Mahajan A, Spracklen CN, Zhang W, Ng MCY, Pety LE, Kitajima H, Yu GZ, Rüeger S, Speidel L, Kim 451 YJ, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse popula�ons for discovery and transla�on. *Nature Genetics*. 2022;54:560-572. doi: 10.1038/s41588-022-01058-3 41. Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan JA, Willems SM, Wu Y, Zhang X, Horikoshi M, et al. The trans-ancestral genomic architecture of glycemic traits. *Nature Genetics*. 2021;53:840-860. doi: 10.1038/s41588-021-00852-9 457 42. Chen M-H, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, Trivedi B, Jiang T, Akbari P, 458 Vuckovic D, et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Popula�ons. *Cell*. 2020;182:1198-1213.e1114. doi: 10.1016/j.cell.2020.06.045 43. Lu X, Liu Z, Cui Q, Liu F, Li J, Niu X, Shen C, Hu D, Huang K, Chen J, et al. A polygenic risk score 461 improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study. *European Heart Journal*. 2022;43:1702-1711. doi: htps://doi.org/10.1093/eurheartj/ehac093 44. Graham SE, Clarke SL, Wu K-HH, Kanoni S, Zajac GJM, Ramdas S, Surakka I, Ntalla I, Vedantam S, 465 Winkler TW, et al. The power of genetic diversity in genome-wide association studies of lipids. *Nature*. 2021;600:675-679. doi: 10.1038/s41586-021-04064-3 467 45. Evans DM, Cardon LR. A Comparison of Linkage Disequilibrium Patterns and Estimated 468 Population Recombination Rates across Multiple Populations. The American Journal of Human *at a seconomia acton Genetics*. 2005;76:681-687. doi: 10.1086/429274

470 46. Cavazos TB, Witte JS. Inclusion of variants discovered from diverse populations improves polygenic risk score transferability. *HGG Adv*. 2021;2:100017. doi: htps://doi.org/10.1016/j.xhgg.2020.100017 473 47. Zhang Y, Qi G, Park J-H, Chatterjee N. Estimation of complex effect-size distributions using 474 summary-level statistics from genome-wide association studies across 32 complex traits. *Nature Genetics*. 2018;50:1318-1326. doi: 10.1038/s41588-018-0193-x 48. Privé F, Aschard H, Carmi S, Folkersen L, Hoggart C, O'Reilly PF, Vilhjálmsson BJ. Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. *The American Journal of Human Genetics*. 2022;109:12-23. doi: 10.1016/j.ajhg.2021.11.008 49. Fahed AC, Aragam KG, Hindy G, Chen Y-DI, Chaudhary K, Dobbyn A, Krumholz HM, Sheu WHH, Rich SS, Roter JI, et al. Transethnic Transferability of a Genome-Wide Polygenic Score for Coronary Artery Disease. *Circulation: Genomic and Precision Medicine*. 2021;14. doi: 10.1161/circgen.120.003092 484 50. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, 485 Khera AV, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Associa�on Task Force on Clinical Prac�ce Guidelines. *Journal of the American College of Cardiology*. 2019;74:177-232. doi: htps://doi.org/10.1016/j.jacc.2019.03.010 51. Volgman AS, Palaniappan LS, Aggarwal NT, Gupta M, Khandelwal A, Krishnan AV, Lichtman JH, Mehta LS, Patel HN, Shah KS, et al. Atherosclero�c Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scien�fic Statement From the American Heart Associa�on. *Circulation*. 2018;138:CIR.00000000000. doi: 10.1161/cir.0000000000000580 494 52. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. *Circulation*. 2014;129:S49-S73. doi: 10.1161/01.cir.0000437741.48606.98 53. Kullo IJ, Jouni H, Olson JE, Montori VM, Bailey KR. Design of a randomized controlled trial of disclosing genomic risk of coronary heart disease: the Myocardial Infarc�on Genes (MI-GENES) study. *BMC Medical Genomics*. 2015;8. doi: 10.1186/s12920-015-0122-0 500 54. The Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium. 501 https://primedconsortium.org/. 2021. 502 55. Atkinson EG, Maihofer AX, Kanai M, Martin AR, Karczewski KJ, Santoro ML, Ulirsch JC, Kamatani Y, Okada Y, Finucane HK, et al. Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and to boost power. *Nature Genetics*. 2021;53:195-204. doi: 10.1038/s41588-020-00766-y 506 56. Cai M, Xiao J, Zhang S, Wan X, Zhao H, Chen G, Yang C. A unified framework for cross-population 507 trait prediction by leveraging the genetic correlation of polygenic traits. The American Journal of *Human Genetics*. 2021;108:632-655. doi: 10.1016/j.ajhg.2021.03.002 57. Weissbrod O, Kanai M, Shi H, Gazal S, Peyrot WJ, Khera AV, Okada Y, Matsuda K, Yamanashi Y, 510 Furukawa Y, et al. Leveraging fine-mapping and multipopulation training data to improve cross-511 population polygenic risk scores. *Nature Genetics*. 2022;54:450-458. doi: 10.1038/s41588-022- 01036-9 58. Amariuta T, Ishigaki K, Sugishita H, Ohta T, Koido M, Dey KK, Matsuda K, Murakami Y, Price AL, Kawakami E, et al. Improving the trans-ancestry portability of polygenic risk scores by priori�zing

# variants in predicted cell-type-specific regulatory elements. *Nature Genetics*. 2020;52:1346-

1354. doi: 10.1038/s41588-020-00740-8

Ancestry	Age <sup>a</sup>	Cases/Controls	<b>Method</b>	<b>AUC<sup>c</sup></b>	OR <sup>d</sup> (95% CI <sup>e</sup> )	P-value	OR (95% CI) Top	P-value
	(mean $\pm$ SD <sup>b</sup> )				per 1 SD		5% vs Rest	
<b>EUR</b>	$52.4 \pm 15.5$	4,970/47,732	$PRS_{P+T}$	0.773	1.65	3.00E-159	2.30	5.71E-55
					$(1.59 - 1.72)$		$(2.07 - 2.56)$	
			<b>PRS<sub>CSx</sub></b>	0.774	1.65	5.19E-171	2.48	5.88E-61
					$(1.59 - 1.71)$		$(2.23 - 2.77)$	
<b>AFR</b>	$53.4 \pm 14.7$	1,359/15,649	$PRS_{P+T}$	0.735	1.16	2.86E-12	1.68	5.51E-08
					$(1.11 - 1.21)$		$(1.39 - 2.03)$	
			<b>PRS<sub>CSx</sub></b>	0.736	1.20	7.46E-14	1.74	3.03E-07
					$(1.15 - 1.26)$		$(1.41 - 2.15)$	
<b>HIS</b>	$54.8 \pm 14.3$	314/5,824	$PRS_{P+T}$	0.699	1.38	5.89E-09	2.16	1.02E-04
					$(1.24 - 1.54)$		$(1.47 - 3.19)$	
			$PRS_{CSx}$	0.706	1.51	7.48E-13	2.57	7.98E-07
					$(1.35 - 1.69)$		$(1.77 - 3.73)$	
EAS	$65.4 \pm 12.9$	6,321/16,430	$PRS_{P+T}$	0.748	1.56	2.97E-146	2.47	1.24E-39
					$(1.50 - 1.61)$		$(2.10-2.90)$	
			<b>PRS<sub>CSx</sub></b>	0.762	1.59	2.41E-160	2.34	1.78E-28
					$(1.54 - 1.64)$		$(2.06 - 2.66)$	
	$53.2 \pm 8.4$	517/8,661	$PRS_{P+T}$	0.786	2.75	9.44E-52	3.95	3.07E-24
SAS					$(2.41 - 3.14)$		$(3.03 - 5.15)$	
			<b>PRS<sub>CSx</sub></b>	0.803	2.67	1.48E-63	4.92	3.90E-34
					$(2.38 - 3.00)$		$(3.81 - 6.35)$	

519 Table 1. Odds Ratios for *incident CHD* for multi-ancestry PRS<sub>P+T</sub> and PRS<sub>CSx</sub> in diverse ancestry cohorts.

520  $\frac{a}{a}$  Age- Age at enrollment<br>521  $\frac{b}{b}$  SD- Standard Deviation

522  $\degree$  AUC-Area under the Curve 523  $\degree$  OR- Odds Ratio 524  $\degree$  CI- Confidence Interval

<sup>e</sup> CI- Confidence Interval

#### 525 **Figures**



527 **Figure 1.** Polygenic Risk Score development using independent MVP cohorts of diverse ancestry.



#### 529



531 represent the GWAS summary statistics used to construct the PRS (green for AFR, purple for EAS, orange for EUR, and grey for the multi-ancestry meta-

- 532 analysis). The Odds Ratios (ORs) per 1 standard deviation (SD) increase with confidence intervals (CIs) in the PRS are represented on the Y-axis and the
- 533 populations on which the PRS is trained are on the X-axis.



534

535 **Figure 3.** Comparison of a prior PRS (metaGRS) and two new PRS using multi-ancestry summary statistics for the prediction of coronary heart

536 disease (CHD) using the ancestrally diverse training cohort of the MVP. Odds Ratios (ORs) per standard deviation (SD) with confidence intervals

- 537 (CIs) are shown for each genetic ancestry group as determined in the methods as a result of metaGRS, P+T, and PRS-CSx PRS methods being
- 538 performed on the MVP training cohort.